Abstracts tagged "fractures"

Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting
Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Silvano Adami⁵, Henry G. Bone⁶, Tobias de Villiers⁷, Douglas P. Kiel⁸, Annie Kung⁹, Prasanna Kumar¹⁰, Sung-Kil Lim¹¹, Xu Ling¹², Kurt Lippuner¹³, Carlos Mautalen¹⁴, Toshitaka Nakamura¹⁵, Jean-Yves Reginster¹⁶, Ian R. Reid¹⁷, José Adolfo Rodríguez-Portales¹⁸, Christian Roux¹⁹, Jesus Walliser²⁰, Nelson B. Watts²¹, José R. Zanchetta²², Cristiano A.F. Zerbini²³, Andrea Rybak-Feiglin²⁴, Dosinda Cohn²⁴, Carolyn A. DaSilva²⁴, Rachid Massaad²⁵, Arthur Santora²⁴, Boyd B. Scott²⁴, Nadia Verbruggen²⁵, Albert Leung²⁶ and Antonio Lombardi²⁴, ¹Oregon Osteoporosis Center, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Department, University of Verona, Verona, Italy, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, ⁹University of Hong Kong, Pokfulam, Hong Kong, China, ¹⁰Bangalore Diabetes Centre, Bangalore, India, ¹¹Yonsei University, Seoul, South Korea, ¹²Peking Union Medical College Hospital, Beijing, China, ¹³Bern University Hospital, Bern, Switzerland, ¹⁴Centro de Osteopatías Médicas, Buenos Aires, Argentina, ¹⁵University of Occupational & Environmental Health, Fukuoaka, Japan, ¹⁶CHU-Centre Ville, Policliniques BRULL, Liege, Belgium, ¹⁷Department of Medicine, University of Auckland, Auckland, New Zealand, ¹⁸Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁹Paris Descartes University, Cochin Hospital, Paris, France, ²⁰Bone Metabolism Clinic, Hospital Angeles del Pedregal, Mexico City, Mexico, ²¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²²IDIM Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina, ²³Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²⁴Merck Sharp and Dohme Corp., Rahway, NJ, ²⁵MSD Europe Inc., Brussels, Belgium, ²⁶Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…
Abstract Number: 2106 • 2014 ACR/ARHP Annual Meeting
Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury
Monique Bethel¹, Lauren Bailey², Frances Weaver², Brian Le³, Stephen Burns⁴, Jelena Svircev⁴, Michael Heggeness⁵ and Laura Carbone⁶, ¹Internal Medicine, Georgia Regents University, Augusta, GA, ²Edward Hines Jr. VA Hospital, Chicago, IL, ³Medicine, Georgia Regents University, Augusta, GA, ⁴VA Puget Sound Healthcare System, Seattle, WA, ⁵Orthopaedic Surgery, University of Kansas School of Medicine, Kansas City, KS, ⁶Medicine, Charlie Norwood VA Medical Center, Augusta, GA
Background/Purpose: Patients with a chronic spinal cord injury (SCI) develop osteoporosis and are at high risk for fracture. However, there is limited information on how…
Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Robert A. Overman¹ and Chad L. Deal², ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…
Abstract Number: 234 • 2014 ACR/ARHP Annual Meeting
The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence
Karine Briot¹, Milka Maravic² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hopital Leopold Bellan, Paris, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose Controversies exist about the change in hip fracture incidence among countries. In France, we previously showed that the incidence of hip fractures decreased in…
Abstract Number: 2114 • 2013 ACR/ARHP Annual Meeting
Hip Fracture Risk Factors To One Year and In-Hospital Mortality , a Prospective Cohort In South Brazil
Tiango Aguiar Ribeiro^1,2, Melissa Orlandin Premaor^2,3, João Alberto Larangeira¹, Michel Luft^1,2, Luiz Giulian Brito¹, Leonardo Waihrich Guterres¹ and Odirlei Andre Monticielo⁴, ¹Department of Orthopedic Surgery and Traumatology, University Hospital of Santa Maria (SOT - HUSM), Federal University of Santa Maria (UFSM), Santa Maria, Brazil, ²Postgraduate Program in Health Sciences, Federal University of Santa Maria (UFSM), Santa Maria, Brazil, ³Department of Clinical Medicine Health Sciences Center (CCS), Federal University of Santa Maria (UFSM), Santa Maria, Brazil, ⁴Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Hip fractures is considered one of the most common and serious injury in the elderly life and have been associated with increased morbidity and…
Abstract Number: 1246 • 2013 ACR/ARHP Annual Meeting
Efficacy Of a 6-Month Treatment With Strontium Ranelate 2g/Day In The Improvement Of Long Bone Fractures With Delayed-Union Or Non-Union
Jean-Marc Feron¹, Vaclav Vyskocil², Carlina Albanese³, Luis Augusto Tavares Russo⁴ and Jean-Denis Laredo⁵, ¹Service de chirurgie orthopédique et traumatologique, Hôpital Saint Antoine, GHU Est , AP-HP, Paris, France, ²Osteocentrum, 3. interní klinika, Všeobecná fakultní nemocnice, U Nemocnice 1, Praha2, Czech Republic, ³Dipartimento di scienze radiologiche, Università degli studi, ROMA, Italy, ⁴CCBR Brasil, Rua Mena Barreto, 33 Botofogo, 22271, Rio de Janeiro, Brazil, ⁵Service Radiologie Ostéo-Articulaire, Hopital Lariboisière, 2, rue Ambroise Paré, 75475, Paris, France
Background/Purpose: To assess the efficacy of strontium ranelate 2g/day in the improvement of healing of peripheral fractures with delayed union or aseptic non-union. Methods: International,…
Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Irene Bultink¹, Nicholas Harvey², Arief Lalmohamed^3,4, Cyrus Cooper⁵, Willem Lems⁶, Tjeerd Van Staa^2,3,7 and Frank de Vries^3,4,8,9, ¹Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands, ⁴Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands, ⁵NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Medicine and Helathcare Products Regulatory Agency, Clinical Practice Research Datalink, London, United Kingdom, ⁸Care and Public Health Research Institute, Maastricht, Netherlands, ⁹Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…
Abstract Number: 1231 • 2013 ACR/ARHP Annual Meeting
The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study
Moa Ivergård¹, Viktor Wintzell¹, László B Tankó², Victoria Barghout³, Axel Svedbom¹, Vidmantas Alekna⁴, Maria Luisa Bianchi⁵, Patricia Clark⁶, Manuel Díaz Curiel^7,8, Hans Peter Dimai⁹, Mikk Jürisson¹⁰, Olga Lesnyak¹¹, Eugene McCloskey¹², Kerrie M Sanders¹³, Thierry Thomas¹⁴, Fredrik Borgström¹⁵ and John A Kanis¹⁶, ¹OptumInsight, Stockholm, Sweden, ²Novartis Pharma AG, Basel, Switzerland, ³VEB HealthCare, Morristown, NJ, ⁴Vilnius University, Faculty of Medicine, Vilnius, Lithuania, ⁵Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy, ⁶Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, ⁷Servicio de Medicina Interna/Enfermedades Metabolicas Osea, Fundacion Jimenez Diaz, Madrid, Spain, ⁸Catedra de Enfermedades Metabolicas Óseas, Universidad Autonoma, Madrid, Spain, ⁹Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, ¹⁰Department of Public Health, Faculty of Medicine, Tartu University, Tartu, Estonia, ¹¹Ural State Medical Academy, Yekaterinburg, Russia, ¹²Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom, ¹³Department of Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, ¹⁴INSERM U1059, CHU-St-Etienne, Saint Etienne, France, ¹⁵LIME/MMC, Karolinska Institutet, Stockholm, Sweden, ¹⁶WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is an ongoing 18 months prospective observational study with the objective of estimating…
Abstract Number: 1233 • 2013 ACR/ARHP Annual Meeting
Strontium Ranelate Uncouples Bone Resorption From Bone Formation In Osteoporotic Patients With Or Without Clinical Risk Factors
Olivier Bruyere¹, Julien Collette² and Jean-Yves Reginster¹, ¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²University of Liege, Labo RIA, CHU Sart Tilman, Liege, Belgium
Background/Purpose: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures in postmenopausal osteoporosis. We explored whether the effect of strontium ranelate on bone turnover…
Abstract Number: 1126 • 2013 ACR/ARHP Annual Meeting
Opportunistic Computed Tomography Screening For Determining Osteoporosis In Patients With Ankylosing Spondylitis and Spine Fractures
Amanda Cagan¹, Osa Emohare¹, Robert Morgan¹, David Polly² and Elie Gertner³, ¹Spine and Spinal Cord Injury, Regions Hospital, Saint Paul, MN, ²Division of Orthopedics, University of Minnesota, Minneapolis, MN, ³Section of Rheumatology, Regions Hospital and University of Minnesota Medical School, St. Paul, MN
Background/Purpose: In advanced disease Ankylosing Spondylitis (AS) is frequently associated with a reduction in bone mineral density (BMD) which contributes to pain and predisposes to…
Abstract Number: 862 • 2013 ACR/ARHP Annual Meeting
Ten-Year Incidence of Self-Reported Nonvertebral Fractures in 9,720 Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study
Kensuke Ochi¹, Takefumi Furuya¹, Eisuke Inoue², Katsunori Ikari¹, Atsuo Taniguchi², Hisashi Yamanaka¹ and Shigeki Momohara², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Ten-Year Incidence of Self-reported Nonvertebral Fractures in 9,720 Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study Background/Purpose: Although rheumatoid arthritis (RA) is a…
Abstract Number: 865 • 2013 ACR/ARHP Annual Meeting
Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses
Johannes Roth¹, Jinhui Ma¹, David A. Cabral², Peter B. Dent³, Janet E. Ellsworth⁴, Adam M. Huber⁵, Kristin M. Houghton², Roman Jurencak¹, Bianca A. Lang⁵, Maggie Larche³, Claire MA Leblanc⁶, Brian Lentle², MaryAnn Matzinger¹, Paivi M. Miettunen⁷, Kiem Oen⁸, Claire Saint-cyr⁹, Rosie Scuccimarri¹⁰, Nazih Shenouda¹, Leanne M. Ward¹ and The Canadian STOPP Consortium¹¹, ¹University of Ottawa, Ottawa, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹National Pediatric Bone Health Working Group, Ottawa, ON, Canada
Background/Purpose: : To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline…
Abstract Number: 379 • 2013 ACR/ARHP Annual Meeting
Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Elena Nikiphorou¹, Lewis Carpenter², Josh Dixey³, Peter Williams⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young⁸, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁴Rheumatology, Medway Maritime Hospital, Gillingham, United Kingdom, ⁵Rheumatology Dept, St George's Hospital, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: The risk of osteoporotic fracture is known to be high in RA. Yet less is known about RA related predictive factors for this…
Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Jean-Pascal Roussy¹, Louis Bessette², Sasha Bernatsky³, Elham Rahme⁴ and Jean Lachaine¹, ¹Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.